Showing 1 posts of 1 posts found.
Onconova Therapeutics says Baxalta has terminated its $565 million agreement to jointly develop the company’s lead drug candidate rigosertib. Baxalta …
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
AstraZeneca’s Trixeo approved in EU for asthma
Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
ESTEVE CDMO adds $17.5m to Illinois expansion